Targeting thapsigargin towards tumors

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Targeting thapsigargin towards tumors. / Doan, Nhu Thi Quynh; Paulsen, Eleonora Sandholdt; Sehgal, Pankaj; Møller, Jesper Vuust; Nissen, Poul; Denmeade, Samuel R; Isaacs, John T; Dionne, Craig A; Christensen, Søren Brøgger.

In: Steroids, Vol. 97, 05.2015, p. 2-7.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Doan, NTQ, Paulsen, ES, Sehgal, P, Møller, JV, Nissen, P, Denmeade, SR, Isaacs, JT, Dionne, CA & Christensen, SB 2015, 'Targeting thapsigargin towards tumors', Steroids, vol. 97, pp. 2-7. https://doi.org/10.1016/j.steroids.2014.07.009

APA

CBE

Doan NTQ, Paulsen ES, Sehgal P, Møller JV, Nissen P, Denmeade SR, Isaacs JT, Dionne CA, Christensen SB. 2015. Targeting thapsigargin towards tumors. Steroids. 97:2-7. https://doi.org/10.1016/j.steroids.2014.07.009

MLA

Vancouver

Author

Doan, Nhu Thi Quynh ; Paulsen, Eleonora Sandholdt ; Sehgal, Pankaj ; Møller, Jesper Vuust ; Nissen, Poul ; Denmeade, Samuel R ; Isaacs, John T ; Dionne, Craig A ; Christensen, Søren Brøgger. / Targeting thapsigargin towards tumors. In: Steroids. 2015 ; Vol. 97. pp. 2-7.

Bibtex

@article{24866ff238404ddaa879c351f60e05f4,
title = "Targeting thapsigargin towards tumors",
abstract = "The skin irritating principle from Thapsia garganica was isolated, named thapsigargin and the structure elucidated. By inhibiting the sarco/endoplasmic reticulum Ca(2+) ATPase (SERCA) thapsigargin provokes apoptosis in almost all cells. By conjugating thapsigargin to peptides, which are only substrates for either prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA) prodrugs were created, which selectively affect prostate cancer cells or neovascular tissue in tumors. One of the prodrug is currently tested in clinical phase II. The prodrug under clinical trial has been named mipsagargin.",
author = "Doan, {Nhu Thi Quynh} and Paulsen, {Eleonora Sandholdt} and Pankaj Sehgal and M{\o}ller, {Jesper Vuust} and Poul Nissen and Denmeade, {Samuel R} and Isaacs, {John T} and Dionne, {Craig A} and Christensen, {S{\o}ren Br{\o}gger}",
note = "Copyright {\circledC} 2014 Elsevier Ltd. All rights reserved.",
year = "2015",
month = "5",
doi = "10.1016/j.steroids.2014.07.009",
language = "English",
volume = "97",
pages = "2--7",
journal = "Steroids",
issn = "0039-128X",
publisher = "Elsevier Inc",

}

RIS

TY - JOUR

T1 - Targeting thapsigargin towards tumors

AU - Doan, Nhu Thi Quynh

AU - Paulsen, Eleonora Sandholdt

AU - Sehgal, Pankaj

AU - Møller, Jesper Vuust

AU - Nissen, Poul

AU - Denmeade, Samuel R

AU - Isaacs, John T

AU - Dionne, Craig A

AU - Christensen, Søren Brøgger

N1 - Copyright © 2014 Elsevier Ltd. All rights reserved.

PY - 2015/5

Y1 - 2015/5

N2 - The skin irritating principle from Thapsia garganica was isolated, named thapsigargin and the structure elucidated. By inhibiting the sarco/endoplasmic reticulum Ca(2+) ATPase (SERCA) thapsigargin provokes apoptosis in almost all cells. By conjugating thapsigargin to peptides, which are only substrates for either prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA) prodrugs were created, which selectively affect prostate cancer cells or neovascular tissue in tumors. One of the prodrug is currently tested in clinical phase II. The prodrug under clinical trial has been named mipsagargin.

AB - The skin irritating principle from Thapsia garganica was isolated, named thapsigargin and the structure elucidated. By inhibiting the sarco/endoplasmic reticulum Ca(2+) ATPase (SERCA) thapsigargin provokes apoptosis in almost all cells. By conjugating thapsigargin to peptides, which are only substrates for either prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA) prodrugs were created, which selectively affect prostate cancer cells or neovascular tissue in tumors. One of the prodrug is currently tested in clinical phase II. The prodrug under clinical trial has been named mipsagargin.

U2 - 10.1016/j.steroids.2014.07.009

DO - 10.1016/j.steroids.2014.07.009

M3 - Journal article

VL - 97

SP - 2

EP - 7

JO - Steroids

JF - Steroids

SN - 0039-128X

ER -